Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma
Background: The aim of this study was to evaluate real-world clinical outcomes and transplant-related complications of allogeneic stem cell transplantation (alloSCT) for Hodgkin lymphoma (HL). Methods: This was a single-centre, retrospective analysis of relapsed and refractory (R/R) HL patients who...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/2/118 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850080618394681344 |
|---|---|
| author | Shiliang Ge Kylie Lepic Ravi Bhindi Tobias Berg Dina Khalaf Brian Leber Michael Radford Irwin Walker Gwynivere Davies Alejandro Garcia-Horton |
| author_facet | Shiliang Ge Kylie Lepic Ravi Bhindi Tobias Berg Dina Khalaf Brian Leber Michael Radford Irwin Walker Gwynivere Davies Alejandro Garcia-Horton |
| author_sort | Shiliang Ge |
| collection | DOAJ |
| description | Background: The aim of this study was to evaluate real-world clinical outcomes and transplant-related complications of allogeneic stem cell transplantation (alloSCT) for Hodgkin lymphoma (HL). Methods: This was a single-centre, retrospective analysis of relapsed and refractory (R/R) HL patients who received an alloSCT between 1 January 2016 and 29 February 2024 in Hamilton, Ontario. The primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS), non-relapse mortality (NRM), and graft-versus-host disease/relapse-free survival (GRFS). Results: Twenty-one patients were identified, with thirteen (62%) pre-treated with programmed death 1 (PD-1) blockade with either nivolumab or pembrolizumab. Seventeen (81%) patients underwent related haploidentical donor transplants, while four (19%) patients received a matched unrelated donor transplant. The 2-year OS and PFS rates were 79% (95% CI: 53–92%) and 63% (95% CI: 37–81%), respectively. Trends towards improved OS, PFS, NRM, and GRFS in PD-1-inhibitor-exposed patients were observed. All PD-1-inhibitor-exposed patients who were in complete remission proceeding to alloSCT remained alive at the last follow-up visit. Among the nine patients in partial remission at the time of alloSCT, three deaths were reported, with a 2-year OS of 61%. Conclusions: Our outcome data of a single-centre, heavily pre-treated cohort of Canadian patients confirm that alloSCT with post-transplant cyclophosphamide-based immunosuppression, which has been associated with improvements in PFS, remains a safe and feasible treatment option for patients with R/R HL in the era of checkpoint inhibitor use. |
| format | Article |
| id | doaj-art-c3aa3d58c4a044f8ba7d1c8b6f91a51d |
| institution | DOAJ |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-c3aa3d58c4a044f8ba7d1c8b6f91a51d2025-08-20T02:44:53ZengMDPI AGCurrent Oncology1198-00521718-77292025-02-0132211810.3390/curroncol32020118Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin LymphomaShiliang Ge0Kylie Lepic1Ravi Bhindi2Tobias Berg3Dina Khalaf4Brian Leber5Michael Radford6Irwin Walker7Gwynivere Davies8Alejandro Garcia-Horton9Department of Medicine, McMaster University, Hamilton, ON L8N 3Z5, CanadaDepartment of Oncology, McMaster University, Hamilton, ON L8V 5C2, CanadaMichael G. DeGroote School of Medicine, McMaster University, Hamilton, ON L8P 1H6, CanadaDepartment of Oncology, McMaster University, Hamilton, ON L8V 5C2, CanadaDepartment of Oncology, McMaster University, Hamilton, ON L8V 5C2, CanadaDepartment of Medicine, McMaster University, Hamilton, ON L8N 3Z5, CanadaDepartment of Oncology, McMaster University, Hamilton, ON L8V 5C2, CanadaDepartment of Medicine, McMaster University, Hamilton, ON L8N 3Z5, CanadaDepartment of Oncology, McMaster University, Hamilton, ON L8V 5C2, CanadaDepartment of Oncology, McMaster University, Hamilton, ON L8V 5C2, CanadaBackground: The aim of this study was to evaluate real-world clinical outcomes and transplant-related complications of allogeneic stem cell transplantation (alloSCT) for Hodgkin lymphoma (HL). Methods: This was a single-centre, retrospective analysis of relapsed and refractory (R/R) HL patients who received an alloSCT between 1 January 2016 and 29 February 2024 in Hamilton, Ontario. The primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS), non-relapse mortality (NRM), and graft-versus-host disease/relapse-free survival (GRFS). Results: Twenty-one patients were identified, with thirteen (62%) pre-treated with programmed death 1 (PD-1) blockade with either nivolumab or pembrolizumab. Seventeen (81%) patients underwent related haploidentical donor transplants, while four (19%) patients received a matched unrelated donor transplant. The 2-year OS and PFS rates were 79% (95% CI: 53–92%) and 63% (95% CI: 37–81%), respectively. Trends towards improved OS, PFS, NRM, and GRFS in PD-1-inhibitor-exposed patients were observed. All PD-1-inhibitor-exposed patients who were in complete remission proceeding to alloSCT remained alive at the last follow-up visit. Among the nine patients in partial remission at the time of alloSCT, three deaths were reported, with a 2-year OS of 61%. Conclusions: Our outcome data of a single-centre, heavily pre-treated cohort of Canadian patients confirm that alloSCT with post-transplant cyclophosphamide-based immunosuppression, which has been associated with improvements in PFS, remains a safe and feasible treatment option for patients with R/R HL in the era of checkpoint inhibitor use.https://www.mdpi.com/1718-7729/32/2/118Hodgkin lymphomaallogeneic stem cell transplantrelapserefractoryPD-1 inhibitor |
| spellingShingle | Shiliang Ge Kylie Lepic Ravi Bhindi Tobias Berg Dina Khalaf Brian Leber Michael Radford Irwin Walker Gwynivere Davies Alejandro Garcia-Horton Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma Current Oncology Hodgkin lymphoma allogeneic stem cell transplant relapse refractory PD-1 inhibitor |
| title | Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma |
| title_full | Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma |
| title_fullStr | Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma |
| title_full_unstemmed | Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma |
| title_short | Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma |
| title_sort | outcomes of allogeneic stem cell transplant in patients with relapsed refractory hodgkin lymphoma |
| topic | Hodgkin lymphoma allogeneic stem cell transplant relapse refractory PD-1 inhibitor |
| url | https://www.mdpi.com/1718-7729/32/2/118 |
| work_keys_str_mv | AT shiliangge outcomesofallogeneicstemcelltransplantinpatientswithrelapsedrefractoryhodgkinlymphoma AT kylielepic outcomesofallogeneicstemcelltransplantinpatientswithrelapsedrefractoryhodgkinlymphoma AT ravibhindi outcomesofallogeneicstemcelltransplantinpatientswithrelapsedrefractoryhodgkinlymphoma AT tobiasberg outcomesofallogeneicstemcelltransplantinpatientswithrelapsedrefractoryhodgkinlymphoma AT dinakhalaf outcomesofallogeneicstemcelltransplantinpatientswithrelapsedrefractoryhodgkinlymphoma AT brianleber outcomesofallogeneicstemcelltransplantinpatientswithrelapsedrefractoryhodgkinlymphoma AT michaelradford outcomesofallogeneicstemcelltransplantinpatientswithrelapsedrefractoryhodgkinlymphoma AT irwinwalker outcomesofallogeneicstemcelltransplantinpatientswithrelapsedrefractoryhodgkinlymphoma AT gwyniveredavies outcomesofallogeneicstemcelltransplantinpatientswithrelapsedrefractoryhodgkinlymphoma AT alejandrogarciahorton outcomesofallogeneicstemcelltransplantinpatientswithrelapsedrefractoryhodgkinlymphoma |